These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 7738606)

  • 1. Pharmacophore refinement of gpIIb/IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides.
    Müller G; Gurrath M; Kessler H
    J Comput Aided Mol Des; 1994 Dec; 8(6):709-30. PubMed ID: 7738606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa.
    Scarborough RM; Naughton MA; Teng W; Rose JW; Phillips DR; Nannizzi L; Arfsten A; Campbell AM; Charo IF
    J Biol Chem; 1993 Jan; 268(2):1066-73. PubMed ID: 8419315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptides.
    Peishoff CE; Ali FE; Bean JW; Calvo R; D'Ambrosio CA; Eggleston DS; Hwang SM; Kline TP; Koster PF; Nichols A
    J Med Chem; 1992 Oct; 35(21):3962-9. PubMed ID: 1433203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A three-residue cyclic scaffold of non-RGD containing peptide analogues as platelet aggregation inhibitors: design, synthesis, and structure--function relationships.
    Stavrakoudis A; Bizos G; Eleftheriadis D; Kouki A; Panou-Pomonis E; Sakarellos-Daitsiotis M; Sakarellos C; Tsoukatos D; Tsikaris V
    Biopolymers; 2000-2001; 56(1):20-6. PubMed ID: 11582574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library.
    O'Neil KT; Hoess RH; Jackson SA; Ramachandran NS; Mousa SA; DeGrado WF
    Proteins; 1992 Dec; 14(4):509-15. PubMed ID: 1438188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro.
    Samanen J; Ali F; Romoff T; Calvo R; Sorenson E; Vasko J; Storer B; Berry D; Bennett D; Strohsacker M
    J Med Chem; 1991 Oct; 34(10):3114-25. PubMed ID: 1920361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides.
    Gurrath M; Müller G; Kessler H; Aumailley M; Timpl R
    Eur J Biochem; 1992 Dec; 210(3):911-21. PubMed ID: 1483474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cation-dependent changes in the binding specificity of the platelet receptor GPIIb/IIIa.
    Kirchhofer D; Gailit J; Ruoslahti E; Grzesiak J; Pierschbacher MD
    J Biol Chem; 1990 Oct; 265(30):18525-30. PubMed ID: 2211716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential antagonism of the interactions of the integrin alpha IIb beta 3 with immobilized glycoprotein ligands by snake-venom RGD (Arg-Gly-Asp) proteins. Evidence supporting a functional role for the amino acid residues flanking the tripeptide RGD in determining the inhibitory properties of snake-venom RGD proteins.
    Lu X; Williams JA; Deadman JJ; Salmon GP; Kakkar VV; Wilkinson JM; Baruch D; Authi KS; Rahman S
    Biochem J; 1994 Dec; 304 ( Pt 3)(Pt 3):929-36. PubMed ID: 7529494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications.
    Andronati SA; Karaseva TL; Krysko AA
    Curr Med Chem; 2004 May; 11(9):1183-211. PubMed ID: 15134514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
    Varon D; Lider O; Dardik R; Shenkman B; Alon R; Hershkoviz R; Kapustina G; Savion N; Martinowitz U; Greenspoon N
    Thromb Haemost; 1993 Dec; 70(6):1030-6. PubMed ID: 8165596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model.
    Imura Y; Stassen JM; Bunting S; Stockmans F; Collen D
    Blood; 1992 Sep; 80(5):1247-53. PubMed ID: 1515641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonists of platelet glycoprotein IIb-IIIa.
    Fisher MJ; Gunn B; Harms CS; Kline AD; Mullaney JT; Nunes A; Scarborough RM; Arfsten AE; Skelton MA; Um SL; Utterback BG; Jakubowski JA
    J Med Chem; 1997 Jun; 40(13):2085-101. PubMed ID: 9207949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation.
    Ali FE; Bennett DB; Calvo RR; Elliott JD; Hwang SM; Ku TW; Lago MA; Nichols AJ; Romoff TT; Shah DH
    J Med Chem; 1994 Mar; 37(6):769-80. PubMed ID: 8145226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solution structure of a cyclic RGD peptide that inhibits platelet aggregation.
    Jois SD; Tambunan US; Chakrabarti S; Siahaan TJ
    J Biomol Struct Dyn; 1996 Aug; 14(1):1-11. PubMed ID: 8877556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and structure--activity relationship studies of a novel and specific peptide motif, Pro-X-X-X-Asp-X, as a platelet fibrinogen receptor antagonist.
    Hayashi Y; Katada J; Sato Y; Igarashi K; Takiguchi Y; Harada T; Muramatsu M; Yasuda E; Uno I
    Bioorg Med Chem; 1998 Mar; 6(3):355-64. PubMed ID: 9568289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD.
    Rahman S; Lu X; Kakkar VV; Authi KS
    Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):223-32. PubMed ID: 7492316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human platelet aggregation by GR91669, a prototype fibrinogen receptor antagonist.
    Foster MR; Hornby EJ; Brown S; Hann M; Kitchin J; Pike N; Ward P
    Thromb Res; 1994 Aug; 75(3):269-84. PubMed ID: 7992238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet GPIIb/IIIa receptor occupancy studies using a novel fluoresceinated cyclic Arg-Gly-Asp peptide.
    Tsao PW; Bozarth JM; Jackson SA; Forsythe MS; Flint SK; Mousa SA
    Thromb Res; 1995 Mar; 77(6):543-56. PubMed ID: 7624840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa).
    Du XP; Plow EF; Frelinger AL; O'Toole TE; Loftus JC; Ginsberg MH
    Cell; 1991 May; 65(3):409-16. PubMed ID: 2018974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.